Xbira 250 mg and 500 mg tablets contain Abiraterone Acetate, a hormonal therapy used in the treatment of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC).
| Composition | Abiraterone Acetate |
| Manufacturer | Cipla Ltd |
| Packing | 120 Tablets in a Bottle |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Zecyte 250mg Tablet contains Abiraterone Acetate, a hormonal therapy used to treat metastatic castration-resistant prostate cancer (mCRPC).
| Composition | Abiraterone Acetate |
| Manufacturer | Cipla Ltd |
| Packing | 120 Tablets in a Bottle |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Bdron 500mg Tablet contains Abiraterone Acetate, a hormonal therapy used in the treatment of advanced prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC).
| Composition | Abiraterone Acetate |
| Manufacturer | BDR Pharmaceuticals |
| Packing | 60 Tablets |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Ahabir 500mg Tablet contains Abiraterone Acetate, a hormonal therapy used in the treatment of metastatic castration-resistant prostate cancer (mCRPC).
| Composition | Abiraterone Acetate |
| Manufacturer | Hetero Drugs Ltd |
| Packing | 60 Tablets |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Abirakast 250mg Tablet contains Abiraterone Acetate and is primarily used in the treatment of advanced prostate cancer.
| Composition | Abiraterone Acetate (250mg) |
| Manufacturer | Aprazer Healthcare Pvt. Ltd. |
| Packing | 120 tablets in 1 bottle |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Abirapro 250mg Tablet contains Abiraterone Acetate, a hormone therapy used in the treatment of advanced prostate cancer.
| Composition | Abiraterone Acetate (250mg) |
| Manufacturer | Glenmark Pharmaceuticals |
| Packing | 120 tablets in 1 bottle |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
